TEL AVIV, June 24, 2026, 16:10 IDT
- Pulsenmore said Ouma Health plans to bring its FDA-authorized home ultrasound system into Ouma’s U.S. virtual maternity care setup.
- Pulsenmore was still in premarket on MarketWatch at the dateline, with Nasdaq regular trading yet to open. MarketWatch showed 19.19 million Pulsenmore shares had moved before the bell.
- The companies did not disclose financial details or say how many patients are covered in the deal.
Pulsenmore Ltd said Wednesday it formed a strategic partnership with Ouma Health to integrate its home ultrasound device into Ouma’s virtual maternity care platform for the U.S. market.
Pulsenmore shares (Nasdaq: PLSM) ended Tuesday at $3.41. Early Wednesday, MarketWatch showed the stock at premarket with 19.19 million shares traded before the bell, far above its 65-day average of 17,740 shares.
The release hit while Tel Aviv was open. TradingHours.com showed TASE trading from 9:59 a.m. to 5:14 p.m. local time on June 24. Nasdaq lists its standard U.S. equity hours as 9:30 a.m. to 4 p.m. ET, with premarket and after-hours sessions also available.
Ouma plans to bring Pulsenmore’s FDA-authorized home ultrasound tech into its virtual maternity care offering. The company’s virtual care uses telehealth and connected devices for pregnancy visits instead of relying only on clinic appointments. Ouma offers services from before conception through postpartum.
Pulsenmore founder and CEO Dr. Elazar Sonnenschein said this partnership might take ultrasound “beyond the walls of the clinic.” Ouma CEO Dr. Sina Haeri said the device could help make virtual maternity care “more clinically complete.”
The companies target patients with limited in-person prenatal care options. March of Dimes calls maternity care deserts any county without a birthing hospital, a birth center with obstetric care, or any obstetric provider. Over 35% of counties across the U.S. fit that description, according to .
Pulsenmore ES is shown in the FDA’s De Novo database as an at-home ultrasound imaging device meant for lay users, with a decision recorded on Oct. 31, 2025. The De Novo pathway is the FDA’s route for devices that are low to moderate risk and don’t have a predicate device yet.
Ouma is expanding in the U.S. too. On June 23, the company said it had extended its maternal-fetal medicine work with MultiCare Health System to cover six outpatient sites and inpatient teleMFM services at Tacoma General Hospital. Maternal-fetal medicine treats high-risk pregnancies.
Pulsenmore is boxed into a small piece of the ultrasound space. GE HealthCare lists Pulsenmore with its Voluson women’s health ultrasound line as a doctor-prescribed at-home product. Butterfly Network has its own FDA-cleared handheld ultrasound line and in March got FDA clearance for an AI tool that dates pregnancies.
Pulsenmore posted 2025 revenue of $12.5 million, up from about $2.6 million in 2024. But $9.6 million of this year’s take came from a one-off GE settlement. Net loss for the year shrank to $5 million from $10 million. Pulsenmore ended the year with $21.7 million in liquid assets.
But Ouma’s statement left out details on price, minimum volume, and when revenue might show up. Pulsenmore flagged that results from the Ouma deal are still just expectations, with risks noted around manufacturing, sales, new markets, partners, capital, regulation, and Middle East volatility.
